E14. The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor positive breast cancer

European Journal of Cancer, Supplement

Volumn 2, Issue 9 SPEC. ISS., 2004, Pages 46-48

  Neven, P ^a   Huang, H J ^a   Vanspauwen, R ^a   Amant, F ^a   Berteloot, P ^a   Van Limbergen, E ^a   Wildiers, H ^a   Paridaens, R ^a   Christiaens, M R ^a   Vergote, I ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DATA BASE; DISEASE MARKER; HUMAN; METASTASIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 9744279181     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.08.013     Document Type: Conference Paper

References (16)

1. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988, 15S1, 15-20.
2. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983, 309, 1343-1347.
3. Fisher ER, Sass R, Fisher B. Pathologic findings from the national surgical adjuvant breast project. Correlations with concordant and discordant oestrogen and progesterone receptors. Cancer 1987, 59, 1554-1559.
4. Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy: S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993, 28, 9-20.
5. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of oestrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988, 6,1076-1087.
6. Robertson JF, Cannon PM, Nicholson RI, Blamey RW. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. Int J Biol Markers 1996, 11, 29-35.
7. Hawkins RA, White G, Bundred NJ. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br J Surg 1987, 74, 1009-1013.
8. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over oestrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21, 1973-1979.
9. Ravdin PM, Green S, Dorr TM. Prognostic significance of progesterone receptor levels in oestrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992, 10, 1284-1291.
10. Elledge RM, Green S, Pugh R et al. Oestrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000, 89, 111-117.
11. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2001, 19, 18-27.
12. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351, 1451-1467.
13. Dowsett M on behalf of the ATAC Trialists' Group. Analysis of time to recurrence in the ATAC trial according to oestrogen and progesterone receptor status. In: Proceedings from the 26th annual San Antonio Breast Cancer Symposium. December 2003, Abstract 4.
14. Ferno M, Stal O, Baldetorp B et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 2000, 59, 69-76.
15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350, 1081-1092.
16. Boccardo F, Rubagotti A, Amoroso D et al. Anastrazole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. In: Proceedings from the 26th annual San Antonio Breast Cancer Symposium. December 2003, Abstract 3.